BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Dev California Life Sciences - ECPv6.1.2.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://dev.califesciences.org
X-WR-CALDESC:Events for Dev California Life Sciences
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230920
DTSTAMP:20260407T062912
CREATED:20220225T015007Z
LAST-MODIFIED:20230518T151004Z
UID:6671-1695081600-1695081600@dev.califesciences.org
SUMMARY:Science of Stability (SOS) Conference
DESCRIPTION:Location: Philadelphia\, PA \n  \nThe Science of Stability (SOS) Conference exposes attendees to the latest discoveries and innovations in the science of stability across different industries that include pharmaceuticals\, generics\, nutraceuticals\, Over-the-Counter (OTC)\, and consumer products. It is a must-attend program for anyone interested in accelerated aging\, degradation chemistry\, and stability. SOS 2022 will be the 7th Science of Stability Conference\, proudly sponsored by FreeThink Technologies\, Inc. \nRegister»
URL:https://dev.califesciences.org/event/science-of-stability-sos-conference/
LOCATION:Science History Institute\, 315 Chestnut Street\, Philadelphia\, PA\, 19106\, United States
CATEGORIES:Member Events
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/02/258762_CLS_22_Event_Graphics-12.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220503T130000
DTEND;TZID=America/Los_Angeles:20220503T160000
DTSTAMP:20260407T062912
CREATED:20220427T163454Z
LAST-MODIFIED:20220427T180520Z
UID:8260-1651582800-1651593600@dev.califesciences.org
SUMMARY:USC - Grand Opening of Three Research Facilities At Michelson Center
DESCRIPTION:Grand Opening of Three Research Facilities @ USC Michelson Center\n\n\n\n\n\n\n\nDean Yannis Yortsos and Dean Amber Miller invite you to the Grand Opening of three state-of-the-art research facilities at the USC Michelson Center for Convergent Bioscience on Tuesday\, May 3rd\, 2022 from 1-4pm. \nHosted by: USC Viterbi School of Engineering and USC Dornsife College of Letters\, Arts and Sciences \nInterdisciplinary research conducted in these facilities is applicable to a variety of industries\, including biotech/biopharma\, aerospace\, advanced materials\, and semiconductor manufacturing. These core facilities enable a thriving research ecosystem; they are open to all members of the USC community and are available to external users. \nAgenda: \n\n1:00pm – Check-In\n1:30pm – Welcome by Deans of Viterbi & Dornsife\n1:45pm – Overview of the three facilities by Directors\n2:00pm – Graduate Research Poster Symposium\, Facility Tours\, and Reception\n\nRegister» \nHosted parking will be available for all guests
URL:https://dev.califesciences.org/event/usc-grand-opening-of-three-research-facilities-at-michelson-center/
LOCATION:USC Michelson Center for Convergent Bioscience\, 1002 Childs Way\, Los Angeles\, CA\, 90089\, United States
CATEGORIES:Industry Supported
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/03/258762_CLS_22_Event_Graphics-13-450x254-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220427
DTSTAMP:20260407T062912
CREATED:20220225T014326Z
LAST-MODIFIED:20220331T205755Z
UID:6669-1650844800-1651017599@dev.califesciences.org
SUMMARY:Stanford Drug Discovery Symposium (SDDS)
DESCRIPTION:Location: Virtual \n  \nAdvances in research and technology now afford us the unique opportunity to develop and test novel diagnostics and therapeutics. This conference takes advantage of the collective experience and expertise of our participants to cover a broad range of policy\, research\, and venture topics. This symposium provides an invaluable forum for interdisciplinary exchange at the forefront of drug research. \n  \nRegister»
URL:https://dev.califesciences.org/event/stanford-drug-discovery-symposium-sdds/
LOCATION:Virtual
CATEGORIES:Industry Supported
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/02/258762_CLS_22_Event_Graphics-12.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220406T120000
DTEND;TZID=America/Los_Angeles:20220406T133000
DTSTAMP:20260407T062912
CREATED:20220318T182641Z
LAST-MODIFIED:20220331T204715Z
UID:6966-1649246400-1649251800@dev.califesciences.org
SUMMARY:USC - Translational Science in the Context of Entrepreneurship
DESCRIPTION:Location: USC Michelson Hall \n  \nTranslation is the process of converting results in basic research into results that directly benefit humans. But what can the path from lab to market look like? Join us on April 6th at the USC Michelson Hall for a live dialogue with experts who will share their translational research journey. \nRegister» \nSpeakers: \nAuriane Gamelin\, MBA Entrepreneurship and Finances\, Co-Founder and COO of OncoXome\, has held operational roles at Fortune 500 companies for over a decade. With this operational experience\, Ms. Gamelin decided to fully commit to advancing cancer research and started OncoXome with her father\, Erick. Auriane earned certifications in drug development processes from UC-Berkeley and completed a training program in clinical investigations at the FDA headquarters. \nDr. Erick Gamelin\, MD\, PhD\, Co-Founder\, CEO & CSO of OncoXome\, Dr. Gamelni is a senior executive in the pharmaceutical industry\, a former professor of oncology\, leader of a research lab\, and a globally renowned expert in oncogenomics and molecular pharmacology. He has dedicated thirty years to oncology\, conducting basic\, translational\, and clinical research both in academia (part of his post-doc at the NIH\, Therapeutic Branch) and in the pharmaceutical industry. While in academia\, Dr. Gamelin participated in bringing several drugs to market such as paclitaxel\, oxaliplatin and nab-paclitaxel. He is a co- inventor on eight international patents and has published more than 140 scientific articles in international peer-reviewed journals. \nValery Fokin\, Ph.D. Professor of Chemistry\, USC\, Valery V. Fokin received his Ph.D. degree in 1998 from the University of Southern California\, where he worked under the direction of Professor Nicos A. Petasis. He then joined the group of Nobel Prize Winner Professor K. Barry Sharpless at The Scripps Research Institute in La Jolla\, California as a postdoctoral fellow\, where he studied catalytic oxidations of olefins. In 2001\, he was appointed assistant\, and in 2006 associate professor in the Chemistry Department at Scripps. His research is centered on understanding of the chemical reactivity and its applications in chemistry\, biology\, and materials science. \nDr Bodhour Salhia Ph.D.\, USC\, Dr. Salhia is a translational genomics scientist with extensive knowledge and expertise in mechanisms that underlie tumorigenesis and tumor biology. She merges cutting edge genomics/epigenomics analyses with cell biological and functional studies towards the investigation of clinically relevant problems in human cancer. She has led and continues to lead numerous DNA methylation studies using a plethora of both array and sequencing based technologies to measure whole genome and targeted CpG methylation changes in a variety of cancer types. \nModerator: \nVasiliki Anest\,Ph.D USC\, Dr. Anest serves as the Chief Innovation Officer for USC Norris. She leads the development of innovation strategies and builds high‐value industry collaborations and strategic partnerships throughout USC and externally. Dr. Anest also serves as Senior Director of Business Development and Industry Relations at the MESH Academy and Business Director of the Rosalie and Harold Rae Brown Center for Cancer Drug Development at USC Norris. She has forged collaborative relationships and formulated unique partnering strategies with university\, government\, and industry partners.
URL:https://dev.califesciences.org/event/translational-science-in-the-context-of-entrepreneurship/
LOCATION:USC Michelson Hall\, 1002 Childs Way\, Los Angeles\, CA\, 90089\, United States
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/03/258762_CLS_22_Event_Graphics-13-450x254-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220406T101500
DTEND;TZID=America/Los_Angeles:20220406T120000
DTSTAMP:20260407T062912
CREATED:20220218T180755Z
LAST-MODIFIED:20220331T204532Z
UID:6483-1649240100-1649246400@dev.califesciences.org
SUMMARY:Johnson & Johnson Innovation - The Search for Solutions to the Delivery Challenges of Nucleic Acid-Based Therapies
DESCRIPTION:Location: Virtual \n  \nGene and nucleic acid therapies are increasingly being established as important modalities for the next generation of medicine. However\, in vivo delivery challenges currently limit their full potential to achieve more widespread clinical use. Scientific innovations are needed to improve the efficiency\, tissue biodistribution\, cellular/ tissue selectivity\, payload capacity\, and immunogenicity to enable therapies with enhanced safety and efficacy profiles. \nIn this webinar\, our panel of scientific experts and entrepreneurs will highlight some of the key delivery challenges facing the field of gene and nucleic acid therapeutics and will discuss select scientific innovations that are being undertaken with the aim to address these challenges. Discussion topics will include both viral and non-viral systems for delivery of DNA\, mRNA\, siRNA/ASO payloads in addition to cell/tissue specific targeting approaches. \nDPDS (Discovery\, Product Development and Supply) of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)’s external innovation team invites innovators with potential solutions to these challenges to apply for an opportunity to meet 1-on-1 to discuss their innovative solutions. \nAreas of particular interest include unmet needs in:\n– Enhanced delivery to retina\, cochlea\, brain\, kidney\, and heart\n– Cell targeting moieties for selective cellular uptake\n– Lipid nanoparticles with cell targeting properties\n– AAV capsid engineering for improved biodistribution\n– Approaches to limit immune surveillance and response \nRegister»
URL:https://dev.califesciences.org/event/the-search-for-solutions-to-the-delivery-challenges-of-nucleic-acid-based-therapies/
LOCATION:Virtual
CATEGORIES:Member Events
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/02/258762_CLS_22_Event_Graphics11.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220325T080000
DTEND;TZID=America/Los_Angeles:20220325T090000
DTSTAMP:20260407T062912
CREATED:20220310T224234Z
LAST-MODIFIED:20220310T224337Z
UID:6894-1648195200-1648198800@dev.califesciences.org
SUMMARY:Halloran Town Hall: Total Data Control and Custody – Moving from Excel to Complete Integration for Better Clinical Trial Decisions
DESCRIPTION:We have certainly come a long way in clinical trial operations over the past few years as our industry collectively shifted to decentralized and hybrid models to collect patient data outside of the traditional site model. And sponsors have a lot of data. This growth\, though celebrated\, also comes with growing pains\, like figuring how to build a large data mapping infrastructure to harness the trial’s data for better insight and oversight. \nIf you’re experiencing a similar issue\, please join our Halloran-hosted virtual Town Hall on March 25\, 2022\, from 11:00a.m. – 12:00p.m. EST on “Total Data Control and Custody: Moving from Excel to Complete Integration for Better Clinical Trial Decisions” led by the global data strategy and innovation team at CSL Behring and joined by experts from Halloran. CSL Behring has recently designed a data infrastructure for their studies that allowed their teams to have better control over their data\, leading to more informed decisions. They have major lessons learned and context behind their change and will be sharing their insights with the panel (and you!) to work through the following: \nHow do you integrate data sources and automate processes to get to a point of total data control regardless of company size? \nHow to get executive buy-in around data standards and oversight? \nWhat does the planning entail? Where do we start? \nIs this the future of data? How should companies prepare? \nIf you too want to evolve in this direction\, there is significant time and money that will need to be spent well in advance of when the trial data needs to be submitted. So\, let’s brainstorm and learn from each other. We hope you can join us – and bring your questions – to talk through scenarios for better data strategy\, control\, and custody for better decision making. \nMeet the Panel: \nMeghan Powers\, Director\, Clinical Practice Operations\, Halloran Consulting Group; Karen Travers\, Associate Principal Consultant\, Organizational & Quality Solutions\, Halloran Consulting Group; Thomas Verish\, Head of Global Data Strategy & Innovation\, CSL Behring; Valerie Reynaert\, Head of Global Clinical Operations\, CSL Behring; Charles Johnson\, Director\, eClinical Operations\, CSL Behring; Tony Ciliberto\, Senior Director\, Global Clinical Operations\, CSL Behring \nRegister» \nUpon registration you will receive a calendar invite with Zoom info.
URL:https://dev.califesciences.org/event/halloran-town-hall-total-data-control-and-custody-moving-from-excel-to-complete-integration-for-better-clinical-trial-decisions/
LOCATION:Live\, Online
CATEGORIES:Industry Supported,Member Events
ATTACH;FMTTYPE=image/jpeg:https://dev.califesciences.org/wp-content/uploads/2022/02/258762_CLS_22_Event_Graphics-12.jpg
END:VEVENT
END:VCALENDAR